Vivos Therapeutics (VVOS) Enterprise Value (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Enterprise Value data on file, last reported at -$2.2 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 2.65% year-over-year to -$2.2 million in Q1 2026; TTM through Mar 2026 was -$2.2 million, a 2.65% increase from a year earlier, with the FY2025 full-year figure at -$2.1 million, up 66.63% from the prior year.
• Enterprise Value for Q1 2026 stood at -$2.2 million, down from -$2.1 million in the prior quarter.
• Over the last five years, Enterprise Value for VVOS reached as high as -$988000.0 in Q3 2023 and fell as low as -$17.8 million in Q1 2022.
• Historically, Enterprise Value has averaged -$5.3 million across 5 years, with a median of -$3.9 million in 2023.
• Across the five-year window, Enterprise Value jumped 85.34% in 2022 and plunged 537.65% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$3.5 million in 2022, then jumped by 53.31% to -$1.6 million in 2023, then slumped by 281.01% to -$6.3 million in 2024, then jumped by 66.63% to -$2.1 million in 2025, then decreased by 7.18% to -$2.2 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$2.2 million in Q1 2026, -$2.1 million in Q4 2025, and -$3.1 million in Q3 2025.